Suppr超能文献

向着一般性癌症发生进化理论发展。

Toward a general evolutionary theory of oncogenesis.

机构信息

Department of Biology, University of Louisville Louisville, KY, USA.

出版信息

Evol Appl. 2013 Jan;6(1):70-81. doi: 10.1111/eva.12023. Epub 2012 Dec 5.

Abstract

We propose an evolutionary framework, the barrier theory of cancer, which is based on the distinction between barriers to oncogenesis and restraints. Barriers are defined as mechanisms that prevent oncogenesis. Restraints, which are more numerous, inhibit but do not prevent oncogenesis. Processes that compromise barriers are essential causes of cancer; those that interfere with restraints are exacerbating causes. The barrier theory is built upon the three evolutionary processes involved in oncogenesis: natural selection acting on multicellular organisms to mold barriers and restraints, natural selection acting on infectious organisms to abrogate these protective mechanisms, and oncogenic selection which is responsible for the evolution of normal cells into cancerous cells. The barrier theory is presented as a first step toward the development of a general evolutionary theory of cancer. Its attributes and implications for intervention are compared with those of other major conceptual frameworks for understanding cancer: the clonal diversification model, the stem cell theory and the hallmarks of cancer. The barrier theory emphasizes the practical value of distinguishing between essential and exacerbating causes. It also stresses the importance of determining the scope of infectious causation of cancer, because individual pathogens can be responsible for multiple essential causes in infected cells.

摘要

我们提出了一个进化框架,即癌症的障碍理论,该理论基于肿瘤发生的障碍和抑制因素之间的区别。障碍被定义为防止肿瘤发生的机制。而抑制因素则更多,它们虽然抑制但不能阻止肿瘤发生。破坏障碍的过程是癌症的根本原因;干扰抑制因素的过程是癌症恶化的原因。障碍理论建立在肿瘤发生涉及的三个进化过程之上:作用于多细胞生物以塑造障碍和抑制因素的自然选择,作用于传染性生物以废除这些保护机制的自然选择,以及导致正常细胞癌变的致癌选择。该理论被提出作为发展癌症一般进化理论的第一步。将其属性和干预意义与其他理解癌症的主要概念框架(克隆多样化模型、干细胞理论和癌症的标志)进行了比较。障碍理论强调了区分根本原因和恶化原因的实际价值。它还强调了确定癌症传染性病因范围的重要性,因为单个病原体可能是感染细胞中多个根本原因的罪魁祸首。

相似文献

1
Toward a general evolutionary theory of oncogenesis.
Evol Appl. 2013 Jan;6(1):70-81. doi: 10.1111/eva.12023. Epub 2012 Dec 5.
2
Joint infectious causation of human cancers.
Adv Parasitol. 2014;84:1-26. doi: 10.1016/B978-0-12-800099-1.00001-6.
3
The evolution of barriers to exploitation: Sometimes the Red Queen can take a break.
Evol Appl. 2021 Aug 4;14(9):2179-2188. doi: 10.1111/eva.13280. eCollection 2021 Sep.
4
Infection, mutation, and cancer evolution.
J Mol Med (Berl). 2012 May;90(5):535-41. doi: 10.1007/s00109-012-0891-2. Epub 2012 Apr 4.
5
An evolutionary perspective on parasitism as a cause of cancer.
Adv Parasitol. 2009;68:21-43. doi: 10.1016/S0065-308X(08)00602-7.
6
The scope of viral causation of human cancers: interpreting virus density from an evolutionary perspective.
Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20180304. doi: 10.1098/rstb.2018.0304.
8
Barrier Displacement on a Neutral Landscape: Toward a Theory of Continental Biogeography.
Syst Biol. 2017 Mar 1;66(2):167-182. doi: 10.1093/sysbio/syw080.
10
Viruses and mobile elements as drivers of evolutionary transitions.
Philos Trans R Soc Lond B Biol Sci. 2016 Aug 19;371(1701). doi: 10.1098/rstb.2015.0442.

引用本文的文献

1
Cancer Genetics in the Arab World.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251336829. doi: 10.1177/15330338251336829. Epub 2025 Apr 22.
2
Evolutionary View of Liver Pathology.
Evol Appl. 2024 Dec 22;17(12):e70059. doi: 10.1111/eva.70059. eCollection 2024 Dec.
3
A phylogenetic review of cancer resistance highlights evolutionary solutions to Peto's Paradox.
Genet Mol Biol. 2022 Dec 5;45(3 Suppl 1):e20220133. doi: 10.1590/1678-4685-GMB-2022-0133. eCollection 2022.
4
The evolution of barriers to exploitation: Sometimes the Red Queen can take a break.
Evol Appl. 2021 Aug 4;14(9):2179-2188. doi: 10.1111/eva.13280. eCollection 2021 Sep.
5
The Shared Use of Extended Phenotypes Increases the Fitness of Simulated Populations.
Front Genet. 2021 Feb 3;12:617915. doi: 10.3389/fgene.2021.617915. eCollection 2021.
6
The special issue on cancer and evolution: Lessons learned.
Evol Appl. 2020 Jul 13;13(7):1784-1790. doi: 10.1111/eva.13040. eCollection 2020 Aug.
7
DNA viruses and cancer: insights from evolutionary biology.
Virusdisease. 2020 Mar;31(1):1-9. doi: 10.1007/s13337-019-00563-0. Epub 2020 Jan 21.
8
The Promising Connection Between Data Science and Evolutionary Theory in Oncology.
Front Oncol. 2020 Jan 20;9:1527. doi: 10.3389/fonc.2019.01527. eCollection 2019.
9
Rosiglitazone enhances the apoptotic effect of 5-fluorouracil in colorectal cancer cells with high-glucose-induced glutathione.
Sci Prog. 2020 Jan-Mar;103(1):36850419886448. doi: 10.1177/0036850419886448. Epub 2019 Nov 10.
10
Differences in mutational processes and intra-tumour heterogeneity between organs: The local selective filter hypothesis.
Evol Med Public Health. 2019 Jun 7;2019(1):139-146. doi: 10.1093/emph/eoz017. eCollection 2019.

本文引用的文献

1
The origin and evolution of mutations in acute myeloid leukemia.
Cell. 2012 Jul 20;150(2):264-78. doi: 10.1016/j.cell.2012.06.023.
2
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.
Nat Rev Cancer. 2012 Jun 14;12(7):487-93. doi: 10.1038/nrc3298.
3
The life history of 21 breast cancers.
Cell. 2012 May 25;149(5):994-1007. doi: 10.1016/j.cell.2012.04.023. Epub 2012 May 17.
4
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.
Lancet Oncol. 2012 Jun;13(6):607-15. doi: 10.1016/S1470-2045(12)70137-7. Epub 2012 May 9.
5
Infection, mutation, and cancer evolution.
J Mol Med (Berl). 2012 May;90(5):535-41. doi: 10.1007/s00109-012-0891-2. Epub 2012 Apr 4.
6
Clonal evolution in cancer.
Nature. 2012 Jan 18;481(7381):306-13. doi: 10.1038/nature10762.
7
Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.
PLoS One. 2011;6(11):e26100. doi: 10.1371/journal.pone.0026100. Epub 2011 Nov 17.
8
The role of the microenvironment in tumor growth and invasion.
Prog Biophys Mol Biol. 2011 Aug;106(2):353-79. doi: 10.1016/j.pbiomolbio.2011.06.006. Epub 2011 Jun 28.
9
Evolved tumor suppression: why are we so good at not getting cancer?
Cancer Res. 2011 Jun 1;71(11):3739-44. doi: 10.1158/0008-5472.CAN-11-0342. Epub 2011 May 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验